From the Journals

ASCO issues guideline for early detection, management of colorectal cancer


 

FROM THE JOURNAL OF GLOBAL ONCOLOGY

The American Society of Clinical Oncology has issued a new guideline on the early detection and management of colorectal cancer in people at average risk for colorectal cancer, which was written by Gilberto Lopes, MD, of the University of Miami and his associates on an ASCO expert panel.

The panel assembled by ASCO to write the guideline consisted of medical oncology, surgical oncology, surgery, gastroenterology, health technology assessment, cancer epidemiology, pathology, radiology, radiation oncology, and patient advocacy experts. Guidelines from eight different developers were examined, and recommendations from those guidelines were adapted to form the new ASCO guideline. The guideline was published in the Journal of Global Oncology.

In people who are asymptomatic, are aged 50-75 years, have no family history of colorectal cancer, are at average risk, and are in settings with high incidences of colorectal cancer, the expert panel recommends guaiac fecal occult blood test or fecal immunochemical testing every 1-2 years, flexible sigmoidoscopy every 5 years, a combination of flexible sigmoidoscopy every 10 years and annual stool-based testing, or colonoscopy every 10 years, depending on available resources. The testing strategy for those with positive stool-based testing or flexible sigmoidoscopy is colonoscopy or a double-contrast barium enema if colonoscopy is unavailable.

For patients who have polyps, polypectomy at the time of colonoscopy is recommended, with the option of referral for surgical resection if not suitable for endoscopic resection. When symptoms (iron-deficiency anemia, bleeding, abdominal pain, and/or change in bowel habits) are present, a colonoscopy should be performed if available. If colonoscopy is contraindicated, a double-contrast barium enema can be performed; if endoscopy is contraindicated, CT colonography can be performed.

More information, including a data supplement with additional evidence tables, a methodology supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources is available at www.asco.org/resource-stratified-guidelines, the guideline noted.

Several members of the expert panel reported conflicts of interest.

SOURCE: Lopes G et al. J Glob Oncol. 2019 Feb 25. doi: 10.1200/JGO.18.00213.

This story was updated on March 4, 2019.

Recommended Reading

Meta-analysis generally supports LI-RADS classification accuracy
MDedge Hematology and Oncology
Liver resection outcomes similar for robotic and open surgery
MDedge Hematology and Oncology
Laparoscopic distal gastrectomy safe alternative to open surgery
MDedge Hematology and Oncology
Pancreatic cancer expression signature is linked to chemoresistance
MDedge Hematology and Oncology
DAAs reduce mortality, cancer risk in HCV study
MDedge Hematology and Oncology
Meta-analysis: Combo therapies best for neuroendocrine tumors
MDedge Hematology and Oncology
FDA approves combo Lonsurf for gastric and GEJ adenocarcinomas
MDedge Hematology and Oncology
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
MDedge Hematology and Oncology
Interactive online module improved detection of Barrett’s esophagus neoplasia
MDedge Hematology and Oncology
ASCO publishes new guideline for treatment, follow-up of early-stage colorectal cancer
MDedge Hematology and Oncology